Main objective is:
* To characterize the evolution of the immuno-virological profile of circulating blood cells and immune aging in patients who had participated to TEMPO-1 in 2007-2008 * To evaluate the role of immune aging and inflammatory profile in the occurrence of comorbidities in HIV-infected individuals over a 15-year period
The alterations that affect the innate and adaptive immune cell compartments in HIV-infected patients are reminiscent of the process of immune aging, characteristic of old age. These alterations, the presumed cause of which is the chronic systemic immune activation established in patients, contribute to the depletion of lymphoid resources which probably leads to the decline of immune competence with the progression of HIV disease.
The comparison between HIV-1-infected patients and uninfected older adults goes beyond the mere appearance of immunosenescence and extends to the deterioration of a number of physiological functions linked to inflammation and to systemic aging.
By inducing persistent and lasting immune activation, HIV-1 infection is now considered a model of accelerated immunosenescence and systemic aging. During this process, the immune system quickly becomes exhausted, because the source of its exhaustion (i.e. HIV) cannot be eliminated.
To determine which factors may contribute to immunosenescence in HIV-1 infection, we propose an extensive immune and virological evaluation in patients who participated in a cross-sectional assessment of immune functions and TEMPO-1 viral reservoirs after 15 years of evolution in order to determine their immune and viral trajectories, to compare these trajectories with the major clinical events and the comorbidities occurring in them.
Previous participation to the TEMPO-1 study
18 years of age or older
HIV-infected individuals and non-HIV infected control group
Be affiliated or beneficiary of a social security scheme
Subject under " sauvegarde de justice " (judicial protection due to temporarily and slightly diminished mental or physical faculties), or under legal guardianship
HIV-infected individuals and non-HIV infected control group
Cohort
Cross-sectional
Not listed
measure of number of participants with the frequency of circulating leukocyte cells
Assessment of 32 biomarkers by Cytek Aurora cytometry to identify more than 15 populations of immune cells
measureof number of participants with the number of hematopoietic stem cells in peripheral blood and their ability to develop a myeloid or lymphoid lineage in culture
Assessment by culture
measure of number of participants with cytokines and chemokines, being associated with the appearance of comorbidities
Assessment by ultra-sensitive manner (Luminex and Quantérix technique)
Measure of number of participants with Microbial translocation markers
Assessment by Elisa technique
Measure of number of participants with the HIV viral reservoir (DNA)
Assessment by HIV DNA viral load (quantitative analysis) and by Sequencing of HIV in its DNA form (qualitative analysis: presence of resistance mutations, stop codons, insertions/deletions)
Click on the lead sponsor to view all of their trials.
